Sign up Australia
Proactive Investors - Run By Investors For Investors

Auris Medical plunges as its Keyzilen tinnitus treatment fails pivotal late-stage study

The Swiss biopharma said late Tuesday that its Keyzilen in-ear injection failed to register a “statistically significant improvement” in tinnitus patients when compared with those receiving the placebo
tinnitus patient
Auris had hoped that Keyzilen would have been the first approved treatment for acute inner ear tinnitus

Auris Medical Holding AG (NASDAQ:EARS) was the top faller on Wall Street on Monday after the Swiss biopharma’s tinnitus treatment candidate failed in a key late-stage study.  

Preliminary top-line data from the TACTT3 trial showed patients taking Keyzilen failed to register a “statistically significant improvement” when compared to those taking a placebo.

“The company is investigating the outcomes, including those in the previously conducted sister trial TACTT2, and will provide an update in due course,” read a statement late on Tuesday.

Had it have been successful, the in-ear injection could have been the first drug to gain approval for treating acute inner ear tinnitus.

Alongside news of the failure, Auris announced a share consolidation which sees one new share issued to investors for every ten of the old shares.

Allowing for the consolidation, shares were down 38.3% to US$1.55 shortly after midday on Monday.

View full EARS profile View Profile

Auris Medical Timeline

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use